Sugi Predict

Sugi Predict / Targets / KCNQ1

KCNQ1

Potassium voltage-gated channel subfamily KQT member 1 · P51787 · KCNQ1 on Sugi Atlas →

42,145 patent compounds predicted against KCNQ1, 28,348 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL367538 SCHEMBL367538 1.00 12/20
SCHEMBL265831 SCHEMBL265831 0.57 12/20
SCHEMBL401818 SCHEMBL401818 0.71 11/20
SCHEMBL203109 SCHEMBL203109 0.54 11/20
SCHEMBL403408 SCHEMBL403408 0.72 9/20
SCHEMBL9148 SCHEMBL9148 0.55 9/20
SCHEMBL403003 SCHEMBL403003 0.68 8/20
SCHEMBL401850 SCHEMBL401850 0.64 8/20
SCHEMBL630938 SCHEMBL630938 0.57 8/20
SCHEMBL630939 SCHEMBL630939 0.57 8/20
SCHEMBL402589 SCHEMBL402589 0.71 7/20
SCHEMBL629837 SCHEMBL629837 0.62 7/20
SCHEMBL629838 SCHEMBL629838 0.62 7/20
SCHEMBL630690 SCHEMBL630690 0.60 7/20
SCHEMBL630691 SCHEMBL630691 0.60 7/20
SCHEMBL404373 SCHEMBL404373 0.58 7/20
SCHEMBL630183 SCHEMBL630183 0.58 7/20
SCHEMBL630184 SCHEMBL630184 0.58 7/20
SCHEMBL630219 SCHEMBL630219 0.58 7/20
SCHEMBL630207 SCHEMBL630207 0.54 7/20

Clinical trials — most relevant to KCNQ1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients PHASE2COMPLETED
Mutation-specific Therapy for the Long QT Syndrome PHASE2COMPLETED
Long QT Syndrome Screening in Newborns PHASE2UNKNOWN
Study to Treat Major Depressive Disorder With a New Medication PHASE2COMPLETED
N-of-1 in ATS and MEPPC PHASE2NOT_YET_RECRUITING
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy PHASE1/PHASE2RECRUITING
A Study of JMT203 in Patients With Cancer Cachexia PHASE1/PHASE2RECRUITING
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss PHASE2COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK PHASE1COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias nanRECRUITING
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Qatar Cardiovascular Biorepository of AF Patients nanUNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism nanCOMPLETED
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy nanUNKNOWN
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia nanUNKNOWN
Characteristics of Andersen-Tawil Syndrome nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome nanCOMPLETED
Prospective Identification of Long QT Syndrome in Fetal Life nanCOMPLETED
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats nanCOMPLETED
Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients nanUNKNOWN
Na+ Channel mRNA Regulation in Heart Failure nanCOMPLETED
Comparing Direct vs Indirect Methods for Cascade Screening nanRECRUITING
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats nanCOMPLETED
Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes nanRECRUITING
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
Clinical Phenotype and Omics Study of KCNQ2-related Epilepsy nanUNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA) nanUNKNOWN
Long QT Syndrome-Population Genetics and Cardiac Studies nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a KCNQ1 binder may also engage these)

ProteinNameSimilarity
Q9TTJ7 — 1.000 Q9TTJ7 →
O97531 — 1.000 O97531 →
O70344 — 0.999 O70344 →
P97414 — 0.999 P97414 →
Q9MYS6 — 0.998 Q9MYS6 →
Q9Z0N7 — 0.998 Q9Z0N7 →
Q9JK97 — 0.997 Q9JK97 →
O88943 — 0.996 O88943 →
KCNQ2 Potassium voltage-gated channel subfamily KQT member 2 0.996 landscape →
Q8K3F6 — 0.995 Q8K3F6 →
Q9Z351 — 0.995 Q9Z351 →
O88944 — 0.995 O88944 →
KCNQ5 Potassium voltage-gated channel subfamily KQT member 5 0.994 landscape →
P58126 — 0.993 P58126 →
KCNQ4 Potassium voltage-gated channel subfamily KQT member 4 0.993 landscape →
Q9JK96 — 0.992 Q9JK96 →
Q9TUI4 — 0.991 Q9TUI4 →
KCNQ3 Potassium voltage-gated channel subfamily KQT member 3 0.989 landscape →
Q9R1T9 — 0.989 Q9R1T9 →
Q9JK45 — 0.988 Q9JK45 →
KCNH3 Voltage-gated inwardly rectifying potassium channel KCNH3 0.988 landscape →
O89047 — 0.987 O89047 →
O73925 — 0.986 O73925 →
Q8WNY2 — 0.986 Q8WNY2 →
P15389 — 0.986 P15389 →
Q9TSZ3 — 0.986 Q9TSZ3 →
KCNH2 Voltage-gated inwardly rectifying potassium channel KCNH2 0.985 landscape →
Q9WVJ0 — 0.985 Q9WVJ0 →
CACNA1H Voltage-dependent T-type calcium channel subunit alpha-1H 0.985 landscape →
Q95167 — 0.984 Q95167 →